FDA’s conclusion about data Reata added to a potentially registrational package for its Friedreich’s ataxia program sliced about $420 million from the company’s market cap, and could complicate the therapy’s path to U.S. approval. The...

Two renal diseases are on track for their first approvals after a pair of Phase III studies hit primary endpoints, suggesting renewed interest in the therapeutic area is paying off for patients and investors....

Limiting the inflammatory side effects of adjuvanted vaccinesA team led by University of Chicago scientists reported in Science Advances that NF-κB modulator SN50 could enable the use of adjuvants to amplify adaptive immune response by...

This story was updated to correct the nature of Imperial College's deal with the U.K. As the U.K. pushes to secure access to several mechanistically diverse vaccines, the country’s procurement deal with GSK and Sanofi...

Two days after FDA granted Fast Track designation to two of BioNTech’s partnered COVID-19 vaccine candidates, one of the products advanced closer to human testing in China. Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196)...

Master protocols for COVID-19 clinical trials are testing half a dozen molecules that aim to prevent respiratory distress in patients with severe disease by targeting the host immune system -- four of these compounds intervene...

Relieving sepsis-related organ damage An ILIAS Biologics Inc. and Korea Advanced Institute of Science and Technology team described in Science Advances a sepsis treatment comprising exosomes loaded with a “super repressor” NF-κB inhibitor: a dominant...

Fudan University develops pan-coronavirus inhibitor A team led by Fudan University researchers has developed a lipopeptide-based pan-coronavirus inhibitor of viral membrane fusion. Described in a preprint on the bioRxiv server, the lipopeptide binds the SARS-CoV-2...

A trio of Weill Cornell and Sloan Kettering researchers have launched Volastra with $12 million in seed funding to develop therapies targeting chromosomal instability -- a driver of cancer metastasis. Polaris Partners led the seed...

Kyoto University team identifies colitis-associated somatic mutations that are lost in colitis-associated cancer to reveal a new colorectal cancer target. A Japanese team has identified novel colorectal cancer targets by contrasting somatic mutations in cancerous...